AVM
RVMD icon

Arch Venture Management’s Revolution Medicines RVMD Stock Holding History

Arch Venture Management’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,233,490
Closed -$92.7M – 9
2023
Q4 		$92.7M Buy
+3,233,490
New +$77.7M 56.72% 1

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Arch Venture Management's RVMD Position: Q1 2024 in Review

Arch Venture Management sold out of Revolution Medicines (RVMD) in Q1 2024, closing a stake of 3,233,490 shares — an estimated $92.7M sold.

Arch Venture Management first reported a position in RVMD in Q4 2023 and held it in 1 quarter. The position peaked at $92.7M in Q4 2023. 210 funds tracked by Wall St. Rank hold RVMD as of Q1 2024.

  • Arch Venture Management reported no remaining Revolution Medicines position as of Q1 2024 after selling out during the quarter.
  • Arch Venture Management sold 3,233,490 Revolution Medicines shares in Q1 2024, an estimated $92.7M.
  • Arch Venture Management first reported a position in Revolution Medicines in Q4 2023 and held it in 1 quarter.
  • Arch Venture Management's Revolution Medicines position peaked at $92.7M in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2024.

Based on Arch Venture Management's 13F filing for Q1 2024, filed 15 May 2024.